We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication
Read MoreHide Full Article
Seagen Inc. recently announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for its marketed drug, Tukysa (tucatinib), in combination with Roche's (RHHBY - Free Report) Herceptin (trastuzumab), to address a new indication.
The sNDA is seeking approval of Tukysa in combination with Herceptin for treating adult patients with HER2-positive colorectal cancer, who have received at least one prior treatment regimen for unresectable or metastatic disease.
Per the company, currently, there is no approved treatment for metastatic colorectal cancer that targets HER2 specifically.
With the FDA granting priority review to the sNDA, a decision from the regulatory body is expected on Jan 19, 2023.
The sNDA was based on data from the pivotal phase II MOUNTAINEER study.
Shares of Seagen have decreased 9.8% this year compared with the industry’s decline of 23.5%.
Image Source: Zacks Investment Research
In May 2022, SGEN announced positive top-line data from the pivotal phase II MOUNTAINEER study, which investigated Tukysa plus Herceptin in patients with previously-treated HER2-positive metastatic colorectal cancer.
The study showed that the combo of Tukysa plus Herceptin demonstrated a confirmed objective response rate of 38.1% per blinded independent central review (“BICR”). The median duration of response was 12.4 months per BICR.
The combination of Tukysa and Herceptin was generally safe and well-tolerated.
The FDA granted Breakthrough Therapy designation to Tukysa in combination with Herceptin in July 2022, for treating adult patients with unresectable or metastatic HER2-positive colorectal cancer, who have previously received fluoropyrimidine, oxaliplatin and irinotecan-containing chemotherapy.
In April 2020, the FDA approved Tukysa in combination with Roche's Herceptin and Xeloda (capecitabine) to treat adult patients with HER2-positive locally advanced or metastatic breast cancer and those who have received at least two prior anti-HER2 treatment regimens.
The European Commission granted marketing authorization to the same Tukysa combo for the same indication in February 2021.
The global phase III MOUNTAINEER-03 study is evaluating Tukysa plus Herceptin and standard chemotherapy versus chemotherapy given with or without cetuximab or bevacizumab for treating first-line HER2-positive metastatic colorectal cancer.
In the first six months of 2022, Tukysa generated sales worth $179.5 million, reflecting an increase of 17% on a year-over-year basis. A potential label expansion of the drug is likely to boost sales further in the days ahead.
Aptose Biosciences’ loss per share estimates narrowed 14% for 2022 and 10% for 2023 in the past 60 days.
Earnings of Aptose Biosciences surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. APTO delivered an earnings surprise of 2.23%, on average.
ORIC Pharmaceuticals’ loss per share estimates narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication
Seagen Inc. recently announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for its marketed drug, Tukysa (tucatinib), in combination with Roche's (RHHBY - Free Report) Herceptin (trastuzumab), to address a new indication.
The sNDA is seeking approval of Tukysa in combination with Herceptin for treating adult patients with HER2-positive colorectal cancer, who have received at least one prior treatment regimen for unresectable or metastatic disease.
Per the company, currently, there is no approved treatment for metastatic colorectal cancer that targets HER2 specifically.
With the FDA granting priority review to the sNDA, a decision from the regulatory body is expected on Jan 19, 2023.
The sNDA was based on data from the pivotal phase II MOUNTAINEER study.
Shares of Seagen have decreased 9.8% this year compared with the industry’s decline of 23.5%.
Image Source: Zacks Investment Research
In May 2022, SGEN announced positive top-line data from the pivotal phase II MOUNTAINEER study, which investigated Tukysa plus Herceptin in patients with previously-treated HER2-positive metastatic colorectal cancer.
The study showed that the combo of Tukysa plus Herceptin demonstrated a confirmed objective response rate of 38.1% per blinded independent central review (“BICR”). The median duration of response was 12.4 months per BICR.
The combination of Tukysa and Herceptin was generally safe and well-tolerated.
The FDA granted Breakthrough Therapy designation to Tukysa in combination with Herceptin in July 2022, for treating adult patients with unresectable or metastatic HER2-positive colorectal cancer, who have previously received fluoropyrimidine, oxaliplatin and irinotecan-containing chemotherapy.
In April 2020, the FDA approved Tukysa in combination with Roche's Herceptin and Xeloda (capecitabine) to treat adult patients with HER2-positive locally advanced or metastatic breast cancer and those who have received at least two prior anti-HER2 treatment regimens.
The European Commission granted marketing authorization to the same Tukysa combo for the same indication in February 2021.
The global phase III MOUNTAINEER-03 study is evaluating Tukysa plus Herceptin and standard chemotherapy versus chemotherapy given with or without cetuximab or bevacizumab for treating first-line HER2-positive metastatic colorectal cancer.
In the first six months of 2022, Tukysa generated sales worth $179.5 million, reflecting an increase of 17% on a year-over-year basis. A potential label expansion of the drug is likely to boost sales further in the days ahead.
Zacks Rank & Stocks to Consider
Seagen currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Aptose Biosciences Inc. (APTO - Free Report) and ORIC Pharmaceuticals, Inc. (ORIC - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aptose Biosciences’ loss per share estimates narrowed 14% for 2022 and 10% for 2023 in the past 60 days.
Earnings of Aptose Biosciences surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. APTO delivered an earnings surprise of 2.23%, on average.
ORIC Pharmaceuticals’ loss per share estimates narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.